C. J. Nelson, G. M. Schneider and D. T. Lysle, “Involvement of Central Mubut not Deltaor Kappa-Opioid Receptors in Immunomodulation,” Brain, Behavior, and Immunity, Vol. 14, No. 3, 2000, pp. 170-184.
 R. T. Rahim, J. J. Meissler Jr., A. Cowan, T. J. Rogerts, E. B. Geller, J. Gaughan, M. W. Adler and T. K. Eisenstein, “Administration of Mu-, Kappaor Delta2-Receptor Agonists via Osmotic Minipumps Suppresses Murine Splenic Antibody Responses,” International Immunopharmacology, Vol. 1, No. 11, 2001, pp. 2001-2009.
 L. Devoino, M. Cheido, E. Alperina and G. Idova, “Evidence for a Role of Dopaminergic Mechanisms in the Immunostimulating Effect of μ-Opioid Receptor Agonist DAGO,” International Journal of Neuroscience, Vol. 113, No. 10, 2003, pp. 1381-1394.
 T. B. Saurer, K. A. Carrigan, S. G. Ijames and D. T. Lysle, “Suppression of Natural Killer Cell Activity by Morphine Is Mediated by the Nucleus Accumbens Shell,” Journal of Neuroimmunology, Vol. 173, No. 1, 2006, pp. 3-11.
 M. A. Cheido and G. V. Idova, “The Differential Contribution of Dopamine D(1) and D(2) Receptors to MuOpioidergic Immunomodulation,” Neuroscience and Behavioral Physiology, Vol. 37, No. 7, 2007, pp. 721-724.
 G. V. Idova, E. L. Alperina and M. A. Cheido, “Contribution of Brain Dopamine, Serotonin and Opioid Receptors in the Mechanisms of Neuroimmunomodulation: Evidence from Pharmacological Analysis,” International Immunopharmacology, Vol. 12, No. 4, 2012, pp. 618-625.
 L. Devoino, E. Alperina, O. Galkina and R. Ilyutchenok, “Involvement of Brain Dopaminergic Structures in Neuroimmunomodulation,” International Journal of Neuroscience, Vol. 91, No. 3-4, 1997, pp. 213-228.
 C. Ulens, M. Van Boven, P. Daenens and J. Tytgat, “Interaction of p-Fluorofentanyl on Cloned Human Opioid Receptors and Exploration of the Role of Trp-318 and His-319 in μ-Opioid Receptor Selectivity,” Journal of Pharmacology and Experimental Therapeutics, Vol. 294, No. 3, 2000, pp. 1024-1033.
 A. Mansour, C. A. Fox, S. Burke, H. Akil and S. Watson, “Immunohistochemical Localization of the Cloned MuOpioid Receptor in the Rat CNS,” Journal of Chemical Neuroanatomy, Vol. 8, No. 4, 1995, pp. 283-305.
 Y. Q. Ding, T. Kaneko, S. Nomura and N. Mizuno, “Immunohistochemical Localization of Mu-Opioid Receptors in the Central Nervous System of the Rat,” Journal of Comparative Neurology, Vol. 367, No. 3, 1996, pp. 375-402.
 L. M. Ambrose, E. M. Unterwald and E. J. Van Bockstaele, “Ultrastructural Evidence for Co-Localization of Dopamine D2 and μ-Opioid Receptors in the Rat Dorsolateral Striatum,” The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, Vol. 279A, No. 1, 2004, pp. 583-591.
 R. Ader, “On the Development of Psychoneuroimmunology,” European Journal of Pharmacology, Vol. 405, No. 1-3, 2000, pp. 167-176.
 E. Gomez-Lazaro, A. Arregi, G. Beitia, O. Vegas, A. Azpiroz and L. Garmendia, “Individual Differences in Chronically Defeated Male Mice: Behavioral, Endocrine, Immune, and Neurotrophic Changes as Markers of Vulnerability to the Effects of Stress,” Stress, Vol. 14, No. 5, 2011, pp. 537-548.
 A. R. Prossin, A. E. Koch, P. L. Campbell, M. G. Mclnnis, S. S. Zalcman and J. K. Zubieta, “Association of Plasma Interleukin-18 Levels with Emotion Regulation and μOpioid Neurotransmitter Function in Major Depression and Healthy Volunteers,” Biological Psychiatry, Vol. 69, No. 8, 2011, pp. 808-812.
 D. F. Avgustinovich, O. V. Alekseenko, I. V. Bakshtanovkaia, L. A. Koriakina, T. V. Lipina, M. V. Tenditnik, N. P. Bondar, I. L. Kovalenko and N. N. Kudriavtseva, “Dynamic Changes of Brain Serotonergic and Dopaminergic Activities during Development of Anxious Depression: Experimental Study,” Uspehi Fiziologicheskich Nauk, Vol. 35, No. 4, 2004, pp. 19-40.
 M. A. Cheido and G. V. Idova, “Immune Response of Submissive and Aggressive Mice under Conditions of Opioid Receptor Activation,” Bulletin of Experimental Biology and Medicine, Vol. 148, No. 6, 2009, pp. 886-888. http://dx.doi.org/10.1007/s10517-010-0843-1
 N. P. Bondar, “Effect of Mu-and Kappa-Opioid Receptor Antagonists on Aggressiveness of Male Mice with Repeated Experience of Aggression,” Rossijiskii Fiziologicheskiji Zhurnal imeni I. M. Sechenova, Vol. 98, No. 6, 2012, pp. 681-692.
 A. J. Cunningham, “A Method of Increased Sensitivity for Detecting Single Antibody Forming Cells,” Nature, Vol. 207, 1965, pp. 1106-1107.
 J. Kowalski, “Immunomodulatory Action of Class Mu-, Deltaand Kappa-Opioid Receptor Agonists in Mice,” Neuropeptides, Vol. 32, No. 4, 1998, pp. 301-306.
 M. A. Cheido and M. M. Gevorgyan, “Peculiarities of the Distribution of Cellular Subpopulations in the Spleen and Peripheral Blood of CBA Mice under Conditions of Activation of the Muand Delta-Opioid Systems,” Immunology, No. 5, 2011, pp. 886-887.
 S. V. Gein, T. A. Baeva, V. O. Nebogatikov and S. P. Tendryakova, “β-Endorphin Effects on Antibody Production, Proliferation, and Secretion of Th1/Th2 Cytokines in Vivo,” Bulletin of Experimental Biology and Medicine, Vol. 152, No. 5, 2012, pp. 595-599.
 S. Ito, T. Mori and T. Sawaguchi, “Differential Effects of Micro-Opioid, Delta-Opioid and Kappa-Opioid Receptor Agonists on Dopamine Receptor Agonist-Induced Climbing Behavior in Mice,” Behavioural Pharmacology, Vol. 17, No. 8, 2006, pp. 691-701.
 E. G. Guy, E. Choi and W. E. Pratt, “Nucleus Accumbens Dopamine and Mu-Opioid Receptors Modulate the Reinstatement of Food-Seeking Behavior by Food-Associated Cues,” Behavioural Brain Research, Vol. 219, No. 2, 2011, pp. 265-272.
 N. N. Kudriavtseva, T. G. Amstislavskaia, D. F. Avgustinovich, I. V. Bakshtanovskaia, T. V. Lipina and O. V. Gorbach, “The Effect of the Repeated Experience of Victories and Defeats in Social Conflicts on the Function of the Brain Serotoninergic System in Male Mice,” Zhurnal Vyssheji Nervnoji Deiatel’nosti imeni I. P. Pavlova, Vol. 46, No. 6, 1996, pp. 1088-1096.
 L. V. Devoino, E. L. Al’perina, E. Podgornaia, O. V. Poliakov, G. V. Idova and RIu. Il’iuchenok, “Involvement of Dopaminergic Systems in the Functional Specialization of Brain Areas during Formation of Aggressive and Submissive Behavior in Mice,” Zhurnal Vyssheji Nervnoji Deiatel’nosti imeni I. P. Pavlova, Vol. 51, No. 2, 2001, pp. 197-205.
 L. Devoino, E. Alperina, E. Podgornaja, R. Ilyutchenok, G. Idova and O. Poljakov, “Regional Changes of Brain Serotonin and Its Metabolite 5-Hydroxyindolacetic Acid and Development of Immunosuppression in Submissive Mice,” International Journal of Neuroscience, Vol. 114, No. 9, 2004, pp. 1049-1062.
 L. Devoino, E. Alperina and T. Pavina, “Immunological Consequences of the Reversal of Social Status in C57BL/ 6J Mice,” Brain, Behavior, and Immunity, Vol. 17, No. 1, 2003, pp. 28-34.
 L. H. Shen, M. H. Liao and Y. C. Tseng, “Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders,” Journal of Biomedicine and Biotechnology, Vol. 2012, 2012, pp. 259-349.
 E. Scarr, T. T. Money, G. Pavey, J. Neo and B. Dean, “Mu Opioid Receptor Availability in People with Psychiatric Disorders Who Died by Suicide: A Case Control Study,” BMC Psychiatry, Vol. 12, 2012, pp. 126-137.
 N. Müller and M. J. Schwarz, “Immune System and Schizophrenia,” Current Immunology Review, Vol. 6, No. 3, 2010, pp. 213-220.
 J. Blume, S. D. Douglas and D. L. Evans, “Immune Suppression and Immune Activation in Depression,” Brain, Behavior, and Immunity, Vol. 25, No. 2, 2011, pp. 221-229. http://dx.doi.org/10.1016/j.bbi.2010.10.008